Basilea Pharmaceutica
BSLN.SW
#5986
Rank
NZ$1.96 B
Marketcap
NZ$158.15
Share price
0.14%
Change (1 day)
49.89%
Change (1 year)

P/E ratio for Basilea Pharmaceutica (BSLN.SW)

P/E ratio at the end of 2025: 16.0

According to Basilea Pharmaceutica's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.8596. At the end of 2025 the company had a P/E ratio of 16.0.

P/E ratio history for Basilea Pharmaceutica from 2004 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202516.0126.26%
20247.05-82.95%
202341.3-17.76%
202250.3-164.35%
2021-78.196.74%
2020-39.750.15%
2019-26.560.45%
2018-16.5-67.06%
2017-50.0181.11%
2016-17.8-5.99%
2015-18.9-28.48%
2014-26.5-20.57%
2013-33.3308.18%
2012-8.1732.08%
2011-6.18-202.93%
20106.01-202.42%
2009-5.87-48.87%
2008-11.5-42.14%
2007-19.8-23.4%
2006-25.9-14.43%
2005-30.2188.64%
2004-10.5

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.